MA-0204
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555298

CAS#: 2095128-17-7 (free acid)

Description: MA-0204 is a highly potent and selective PPARd modulator (PPARδ EC50 = 0.4 nM; PPARalpha, EC50 == 6,660 nM) that upregulates the expression of FAO genes in human renal proximal tubule cells, resulting in increased mitochondrial fatty acid oxidation. In normal rats undergoing IR-AKI, MA-0204 attenuates the increases of plasma and urinary biomarkers of AKI, improves renal function, mitigates proximal tubular damage and boosts mitochondrial gene expression. MA-0204 is a potential Treatment for Duchenne Muscular Dystrophy (DMD)


Chemical Structure

img
MA-0204
CAS# 2095128-17-7 (free acid)

Theoretical Analysis

MedKoo Cat#: 555298
Name: MA-0204
CAS#: 2095128-17-7 (free acid)
Chemical Formula: C25H27F3N2O4
Exact Mass: 476.1923
Molecular Weight: 476.4962
Elemental Analysis: C, 63.02; H, 5.71; F, 11.96; N, 5.88; O, 13.43

Price and Availability

Size Price Availability Quantity
100.0mg USD 1450.0 2 Weeks
200.0mg USD 1950.0 2 Weeks
500.0mg USD 2950.0 2 Weeks
1.0g USD 4250.0 2 Weeks
2.0g USD 6950.0 2 Weeks
Bulk inquiry

Related CAS #: 2095128-30-4   2095128-17-7 (free acid)    

Synonym: MA-0204; MA 0204; MA0204.

IUPAC/Chemical Name: (R)-3-methyl-6-(2-((5-methyl-2-(4-(trifluoromethoxy)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoic acid

InChi Key: GYNMVDMBFKGCCR-QGZVFWFLSA-N

InChi Code: InChI=1S/C25H27F3N2O4/c1-17(14-23(31)32)6-5-13-33-22-8-4-3-7-20(22)16-30-18(2)15-29-24(30)19-9-11-21(12-10-19)34-25(26,27)28/h3-4,7-12,15,17H,5-6,13-14,16H2,1-2H3,(H,31,32)/t17-/m1/s1

SMILES Code: O=C(O)C[C@H](C)CCCOC1=CC=CC=C1CN2C(C)=CN=C2C3=CC=C(OC(F)(F)F)C=C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 476.4962 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD)
Bharat Lagu, Arthur F. Kluge, Effie Tozzo, Ross Fredenburg, Eric L. Bell, Matthew M. Goddeeris, Peter Dwyer, Andrew Basinski, Ramesh S. Senaiar, Mahaboobi Jaleel, Nirbhay Kumar Tiwari, Sunil K. Panigrahi, Narasimha Rao Krishnamurthy, Taisuke Takahashi, and Michael A. Patane
Publication Date (Web): July 31, 2018 (Letter)
DOI: 10.1021/acsmedchemlett.8b00287

MA-0204

100.0mg / USD 1450.0


Additional Information

MA-0204 was tested in vivo in mice and in vitro in patientderived muscle myoblasts (from Duchenne Muscular Dystrophy (DMD) patients); MA-0204 altered the expression of PPARδ target genes and improved fatty acid oxidation, which supports the therapeutic hypothesis for the study of MA-0204 in DMD patients.